NASDAQ · SCNI
Healthcare · Biotechnology
$0.45
Down-$0.02 (-4.92%)
Updated Nov 5, 2026, 9:14 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SCNI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
SCNI closed at $0.45 after 21 trading sessions, down 60.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.44 | $0.472 | $0.44 | $0.4488 | 14.72K |
| Nov 3, 2026 | $0.462 | $0.494 | $0.3901 | $0.472 | 98.95K |
| Nov 2, 2026 | $0.472 | $0.50 | $0.4159 | $0.4742 | 167.61K |
| Oct 30, 2026 | $0.545 | $0.545 | $0.47 | $0.4716 | 52.95K |
| Oct 29, 2026 | $0.5637 | $0.5637 | $0.51 | $0.5185 | 46.01K |
| Oct 28, 2026 | $0.536 | $0.5514 | $0.503 | $0.5341 | 39.41K |
| Oct 27, 2026 | $0.55 | $0.57 | $0.52 | $0.531 | 50.19K |
| Oct 26, 2026 | $0.5179 | $0.574 | $0.5179 | $0.5415 | 122.31K |
| Oct 23, 2026 | $0.5787 | $0.5938 | $0.5451 | $0.5645 | 42.64K |
| Oct 22, 2026 | $0.5689 | $0.642 | $0.5689 | $0.6109 | 137.84K |
| Oct 21, 2026 | $0.69 | $0.69 | $0.55 | $0.6102 | 186.99K |
| Oct 20, 2026 | $0.74 | $0.74 | $0.6726 | $0.6813 | 130.1K |
| Oct 19, 2026 | $0.7498 | $0.7511 | $0.66 | $0.75 | 110.91K |
| Oct 16, 2026 | $0.833 | $0.8995 | $0.732 | $0.7524 | 225.22K |
| Oct 15, 2026 | $0.7862 | $0.943 | $0.76 | $0.9015 | 379.08K |
| Oct 14, 2026 | $0.782 | $0.9511 | $0.75 | $0.88 | 2.72M |
| Oct 13, 2026 | $1.56 | $1.76 | $1.1401 | $1.23 | 64.1M |
| Oct 12, 2026 | $1.18 | $1.20 | $1.105 | $1.16 | 43.27K |
| Oct 9, 2026 | $1.22 | $1.23 | $1.18 | $1.18 | 20.35K |
| Oct 8, 2026 | $1.11 | $1.23 | $1.06 | $1.21 | 90.57K |
| Oct 7, 2026 | $1.20 | $1.23 | $1.12 | $1.13 | 40.44K |
The latest Smart Investors Daily articles mentioning SCNI.
Company
Market Activity
Research & News
SCNI research
Company profile and research snapshot.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Yahoo · Oct 20, 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) today issued the following letter to shareholders from Chief Executive Officer Amir Reichman.
Yahoo · Oct 16, 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company operating a growing contract development and manufacturing organization ("CDMO") alongside an immunology-focused therapeutic development platform, today announced the closing of its previously announced private placement of 2,458,334 American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), each ADS representing 40,000 ordinary shares, together with Series A-1 Warrants to pu
ChartMill · Oct 14, 2026
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCNI.
No results
No recent SID articles mention SCNI.
